Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD ‐11-Reference-Cited by-同舟云学术

Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD ‐11

Published:2021-09-14 Issue:12 Volume:23 Page:2819-2824
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Frias Juan P.¹^ORCID,Bonora Enzo²,Cox David A.³^ORCID,Bethel M. Angelyn³,Kwan Anita Y.M.³,Raha Sohini³,Malik Raleigh E.³^ORCID

Affiliation:

1. National Research Institute Los Angeles California USA

2. University and University Hospital of Verona Verona Italy

3. Eli Lilly and Company Indianapolis Indiana USA

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14533

Reference13 articles.

1. Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm – 2016 EXECUTIVE SUMMARY

2. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021

3. Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs)

4. Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A study of factors influencing long-term glycemic variability in patients with type 2 diabetes: a structural equation modeling approach;Frontiers in Endocrinology;2023-07-31